Texas A&M, GlaxoSmithKline Join on $91 million Flu-Vaccine Manufacturing Facility

The project reportedly will create billions in expenditures annually and create 7,000 jobs.

The Texas A&M University System on Tuesday announced a partnership with pharmaceutical giant GlaxoSmithKline to create a $91 million influenza vaccine-manufacturing facility in Bryan-College Station that officials said will generate billions of dollars worth of expenditures per year and will create close to 7,000 jobs.

Gov. Rick Perry headlined the event and said the TAMUS influenza vaccine-manufacturing center will facilitate a rapid national vaccine response.

No votes yet

GlaxoSmithKline Treatment for Systemic Lupus Erythematosus Shows Promise

The firm reports that physicians are highly satisfied with the treatment’s clinical response.

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that physicians currently using GlaxoSmithKline/Human Genome Science’s Benlysta (belimumab) for their moderate-to-severe SLE patients are highly satisfied with its clinical response.

No votes yet

GSK, Theravance Attain Approval for New COPD Treatment

The FDA has approved the new drug application for a once-daily medication for patients with chronic obstructive pulmonary disease.

GlaxoSmithKline plc (GSK) and Theravance, Inc. today announced that the New Drug Application (NDA) for the once-daily investigational medicine fluticasone furoate "FF"/vilanterol "VI" (FF/VI) for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the US Food and Drug Administration (FDA) indicating that the application is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date has also been confirmed as 12 th May 2013.

No votes yet

GlaxoSmithKline Ships New U.S. Flu Vaccine

The company has started shipping two new influenza vaccines for the 2012-13 season.

GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval® (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This follows approval of this season's GSK seasonal influenza vaccines by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research.

No votes yet

GlaxoSmithKline Increases Ownership in Theravance

The companies will partner to further treatments for asthma and COPD.

GlaxoSmithKline plc and Theravance, Inc. announced today that following approval by Theravance, Inc.'s stockholders at their Annual Meeting held on 15 May 2012, and expiration of applicable waiting periods under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976, GSK's acquisition of 10,000,000 shares of Theravance common stock on the terms previously announced on 2 April 2012, has now completed.

As a result, GSK now owns 25,814,421 shares of Theravance common stock, approximately 26.7% of the total outstanding capital stock of Theravance.

No votes yet
Syndicate content